Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the cirrhotic rat liver

Hepatology Research

Volumn 13, Issue 1, 1998, Pages 1-9

  Kitayama, Yoshthiro ^a   Yamanaka, Naoki ^a   Okamoto, Eizo ^a   Kusumoto, Keiji ^b   Fujiwara, Akemi ^b   Watanabe, Toshifumi ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Takeda Chemical Industries Ltd   (Japan)

Author keywords

Endothelin 1; Liver cirrhosis; Liver ischemia; New endothelin receptor antagonist; Reperfusion injury

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; TAK 044; THIOACETAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SWELLING; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG MECHANISM; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CELL; LIVER CIRRHOSIS; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 0032415267     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(98)00062-x     Document Type: Article

References (17)

1. Masaki T Reduced sensitivity of vascular response to endothelin. Circulation. 87((Suppl V)):1993;v33-v35.
2. Goto M, Takei Y, Kawano S et al. Endothelin-1 is involved in the pathogenesis of ischemia/reperfusion liver injury by hepatic microcirculatory disturbances. Hepatology. 19:1994;675-681.
3. Okumura S, Takei Y, Kawano S et al. Vasoactive effect of endothelin-1 on rat liver in vivo. Hepatology. 19:1994;155-161.
4. Kawamura E, Yamanaka N, Okamoto E et al. Response of plasma and tissue endothelin- 1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology. 21:1995;1138-1143.
5. A) antagonist isolated from Streptomyces misakiensis. Biochem Biophys Res Commun. 178:1991;132-137.
6. Ihare M, Noguchi K, Saeki T et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 50:1992;247-255.
7. Sogabe K, Nirei H, Shoubo M et al. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 264:1993;1040-1046.
8. 15) endothelin-1(11-21). FEBS Lett. 311:1992;12-16.
9. Ishikawa K, Ihare M, Noguchi K et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA. 91:1994;4892-4896.
10. Tanaka T, Tsukuda E, Nozawa M et al. RES-701-1, a novel, potent, endothelin type B receptor-selective antagonist of microbial origin. Mol Pharmacol. 45:1994;724-730.
11. Clozel M, Gray GA, Breu V et al. The endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun. 186:1992;867-873.
12. Mcmurdo L, Corder R, Triemermann C et al. Incomplete inhibition of the pressor effects of endothelin- 1 and related peptides in the anaesthetized rat with BQ 123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol. 108:1993;557-561.
13. Ikeda S, Awane Y, Kusumoto K et al. A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA and ETB mediated blood pressure responses in rats. J Pharmacol Exp Ther. 270(2):1994;728-733.
14. Kitayama Y, Yamanaka N, Kawamura E et al. Hapatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the liver. Hepatology. 25:1997;938-942.
15. Kretzschmar M, Franke H, Zimmermann T et al. Glutathione synthesis and export in experimental liver cirrhosis induced by thioacetamide: relations to ultrastructual changes. Exp Pathol. 36:1989;113-122.
16. Miller LL Technic of liver perfusion. Bartosek I, Guaitani A, Miller LL Isolated Liver Perfusion and Its Applications. 1973;11-52 Raven Press, New York.
17. Watanabe T, Awane Y, Ikeda S et al. Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 114:1995;949-954.